304 related articles for article (PubMed ID: 32308618)
1. Mitochondrial Dysfunction and Parkinson's Disease-Near-Infrared Photobiomodulation as a Potential Therapeutic Strategy.
Foo ASC; Soong TW; Yeo TT; Lim KL
Front Aging Neurosci; 2020; 12():89. PubMed ID: 32308618
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial Dysfunction in Parkinson's Disease: From Mechanistic Insights to Therapy.
Gao XY; Yang T; Gu Y; Sun XH
Front Aging Neurosci; 2022; 14():885500. PubMed ID: 35795234
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
4. Photobiomodulation for Parkinson's Disease in Animal Models: A Systematic Review.
Salehpour F; Hamblin MR
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326425
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's Disease and Photobiomodulation: Potential for Treatment.
Bicknell B; Liebert A; Herkes G
J Pers Med; 2024 Jan; 14(1):. PubMed ID: 38276234
[TBL] [Abstract][Full Text] [Related]
6. Pre-conditioning with Remote Photobiomodulation Modulates the Brain Transcriptome and Protects Against MPTP Insult in Mice.
Ganeshan V; Skladnev NV; Kim JY; Mitrofanis J; Stone J; Johnstone DM
Neuroscience; 2019 Feb; 400():85-97. PubMed ID: 30625333
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial dysfunction in Parkinson's disease.
Hu Q; Wang G
Transl Neurodegener; 2016; 5():14. PubMed ID: 27453777
[TBL] [Abstract][Full Text] [Related]
8. Effects of transcranial photobiomodulation with near-infrared light on sexual dysfunction.
Cassano P; Dording C; Thomas G; Foster S; Yeung A; Uchida M; Hamblin MR; Bui E; Fava M; Mischoulon D; Iosifescu DV
Lasers Surg Med; 2019 Feb; 51(2):127-135. PubMed ID: 30221776
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson's disease models in vitro and vivo.
Li H; Sun B; Huang Y; Zhang J; Xu X; Shen Y; Chen Z; Yang J; Shen L; Hu Y; Gu H
Mol Med; 2022 Mar; 28(1):29. PubMed ID: 35255803
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of Na
Xing R; Liu X; Tian B; Cheng Y; Li L
Drug Dev Res; 2021 Nov; 82(7):969-979. PubMed ID: 33538000
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
12. Intracranial application of near-infrared light in a hemi-parkinsonian rat model: the impact on behavior and cell survival.
Reinhart F; Massri NE; Chabrol C; Cretallaz C; Johnstone DM; Torres N; Darlot F; Costecalde T; Stone J; Mitrofanis J; Benabid AL; Moro C
J Neurosurg; 2016 Jun; 124(6):1829-41. PubMed ID: 26613166
[TBL] [Abstract][Full Text] [Related]
13. Brain Photobiomodulation Therapy: a Narrative Review.
Salehpour F; Mahmoudi J; Kamari F; Sadigh-Eteghad S; Rasta SH; Hamblin MR
Mol Neurobiol; 2018 Aug; 55(8):6601-6636. PubMed ID: 29327206
[TBL] [Abstract][Full Text] [Related]
14. Current Progress of Mitochondrial Quality Control Pathways Underlying the Pathogenesis of Parkinson's Disease.
Jiang X; Jin T; Zhang H; Miao J; Zhao X; Su Y; Zhang Y
Oxid Med Cell Longev; 2019; 2019():4578462. PubMed ID: 31485291
[TBL] [Abstract][Full Text] [Related]
15. Transcranial and systemic photobiomodulation for major depressive disorder: A systematic review of efficacy, tolerability and biological mechanisms.
Caldieraro MA; Cassano P
J Affect Disord; 2019 Jan; 243():262-273. PubMed ID: 30248638
[TBL] [Abstract][Full Text] [Related]
16. Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.
Paudel YN; Angelopoulou E; Piperi C; Shaikh MF; Othman I
Pharmacol Res; 2020 Feb; 152():104593. PubMed ID: 31843673
[TBL] [Abstract][Full Text] [Related]
17.
Mallach A; Weinert M; Arthur J; Gveric D; Tierney TS; Alavian KN
FASEB J; 2019 Jun; 33(6):6957-6961. PubMed ID: 30862197
[TBL] [Abstract][Full Text] [Related]
18. IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson's disease.
Kim H; Kim SH; Cha H; Kim SR; Lee JH; Park JW
Free Radic Res; 2016 Aug; 50(8):853-60. PubMed ID: 27142242
[TBL] [Abstract][Full Text] [Related]
19. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial Dysfunction and Parkinson's Disease: Pathogenesis and Therapeutic Strategies.
Moradi Vastegani S; Nasrolahi A; Ghaderi S; Belali R; Rashno M; Farzaneh M; Khoshnam SE
Neurochem Res; 2023 Aug; 48(8):2285-2308. PubMed ID: 36943668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
